Industry Growth Insights published a new data on “Bio-pharma Market”. The research report is titled “Bio-pharma Market research by Types (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins, Others), By Applications (Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases, Others), By Players/Companies Pfizer, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Sanofi, Amgen, AbbVie, Merck & Co., Inc, Biogen Idec, Bayer AG, Eli Lilly and Company, Novartis AG GlaxoSmithKline Plc, Pfizer, AstraZeneca PLC, Abbott Laboratories”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Bio-pharma Market Research Report
By Type
Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins, Others
By Application
Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases, Others
By Companies
Pfizer, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Sanofi, Amgen, AbbVie, Merck & Co., Inc, Biogen Idec, Bayer AG, Eli Lilly and Company, Novartis AG GlaxoSmithKline Plc, Pfizer, AstraZeneca PLC, Abbott Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Bio-pharma Market Report Segments:
The global Bio-pharma market is segmented on the basis of:
Types
Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- F. Hoffmann-La Roche AG
- Johnson & Johnson Services
- Sanofi, Amgen
- AbbVie
- Merck & Co., Inc
- Biogen Idec
- Bayer AG
- Eli Lilly and Company
- Novartis AG GlaxoSmithKline Plc
- Pfizer
- AstraZeneca PLC
- Abbott Laboratories
Highlights of The Bio-pharma Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Recombinant Proteins
- Granulocyte-Colony Stimulating Factor (G-CSF)
- Interferons
- Recombinant Human Insulin
- Erythropoietin
- Vaccines
- Growth Hormones
- Purified Proteins
- Others
- By Application:
- Metabolic Disorders
- Oncology
- Neurological Disorders
- Cardiovascular Diseases
- Inflammatory and Infectious Diseases
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bio-pharma Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bio-pharma is the pharmaceutical industry that produces drugs from living organisms.
Some of the key players operating in the bio-pharma market are Pfizer, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Sanofi, Amgen, AbbVie, Merck & Co., Inc, Biogen Idec, Bayer AG, Eli Lilly and Company, Novartis AG GlaxoSmithKline Plc, Pfizer, AstraZeneca PLC, Abbott Laboratories.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bio-pharma Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bio-pharma Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bio-pharma Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bio-pharma Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bio-pharma Market Size & Forecast, 2020-2028
4.5.1 Bio-pharma Market Size and Y-o-Y Growth
4.5.2 Bio-pharma Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Recombinant Proteins
5.2.3 Granulocyte-Colony Stimulating Factor (G-CSF)
5.2.4 Interferons
5.2.5 Recombinant Human Insulin
5.2.6 Erythropoietin
5.2.7 Vaccines
5.2.8 Growth Hormones
5.2.9 Purified Proteins
5.2.10 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Metabolic Disorders
6.2.2 Oncology
6.2.3 Neurological Disorders
6.2.4 Cardiovascular Diseases
6.2.5 Inflammatory and Infectious Diseases
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bio-pharma Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bio-pharma Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Recombinant Proteins
9.6.3 Granulocyte-Colony Stimulating Factor (G-CSF)
9.6.4 Interferons
9.6.5 Recombinant Human Insulin
9.6.6 Erythropoietin
9.6.7 Vaccines
9.6.8 Growth Hormones
9.6.9 Purified Proteins
9.6.10 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Metabolic Disorders
9.10.2 Oncology
9.10.3 Neurological Disorders
9.10.4 Cardiovascular Diseases
9.10.5 Inflammatory and Infectious Diseases
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Recombinant Proteins
10.6.3 Granulocyte-Colony Stimulating Factor (G-CSF)
10.6.4 Interferons
10.6.5 Recombinant Human Insulin
10.6.6 Erythropoietin
10.6.7 Vaccines
10.6.8 Growth Hormones
10.6.9 Purified Proteins
10.6.10 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Metabolic Disorders
10.10.2 Oncology
10.10.3 Neurological Disorders
10.10.4 Cardiovascular Diseases
10.10.5 Inflammatory and Infectious Diseases
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Recombinant Proteins
11.6.3 Granulocyte-Colony Stimulating Factor (G-CSF)
11.6.4 Interferons
11.6.5 Recombinant Human Insulin
11.6.6 Erythropoietin
11.6.7 Vaccines
11.6.8 Growth Hormones
11.6.9 Purified Proteins
11.6.10 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Metabolic Disorders
11.10.2 Oncology
11.10.3 Neurological Disorders
11.10.4 Cardiovascular Diseases
11.10.5 Inflammatory and Infectious Diseases
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Recombinant Proteins
12.6.3 Granulocyte-Colony Stimulating Factor (G-CSF)
12.6.4 Interferons
12.6.5 Recombinant Human Insulin
12.6.6 Erythropoietin
12.6.7 Vaccines
12.6.8 Growth Hormones
12.6.9 Purified Proteins
12.6.10 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Metabolic Disorders
12.10.2 Oncology
12.10.3 Neurological Disorders
12.10.4 Cardiovascular Diseases
12.10.5 Inflammatory and Infectious Diseases
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Recombinant Proteins
13.6.3 Granulocyte-Colony Stimulating Factor (G-CSF)
13.6.4 Interferons
13.6.5 Recombinant Human Insulin
13.6.6 Erythropoietin
13.6.7 Vaccines
13.6.8 Growth Hormones
13.6.9 Purified Proteins
13.6.10 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Metabolic Disorders
13.10.2 Oncology
13.10.3 Neurological Disorders
13.10.4 Cardiovascular Diseases
13.10.5 Inflammatory and Infectious Diseases
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bio-pharma Market: Competitive Dashboard
14.2 Global Bio-pharma Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 F. Hoffmann-La Roche AG
14.3.3 Johnson & Johnson Services
14.3.4 Sanofi, Amgen
14.3.5 AbbVie
14.3.6 Merck & Co., Inc
14.3.7 Biogen Idec
14.3.8 Bayer AG
14.3.9 Eli Lilly and Company
14.3.10 Novartis AG GlaxoSmithKline Plc
14.3.11 Pfizer
14.3.12 AstraZeneca PLC
14.3.13 Abbott Laboratories
